I'm sorry to read that, I was doubting they were going to finish the App until I saw today's RNS. So they might be even pull it off and present a decent looking App, that we can all download from the app stores and play with. I Don't know what to make about that other company buying 14% of the shares either
RE: Ramp crew have fecked off now29 May 2020 11:31
The RNS is a surprise to me, that means they at least have a decent looking App, enough to bring a little hospital in for trials. That's more than I expected, there could be a positive outcome from the trial, a good report and then the App is out of beta and ready
RE: Let’s not forget what’s in store21 May 2020 08:19
Most scientists say the pandemics will go on for two years, leaked Pentagon memo says don't expect viable vaccination until summer 2021, new strain detected in China with longer incubation period (making PCRs tests more important). Novacyt is in for a longer play than people think, it should keep strong sales for a few quarters to come
It's not blockchain's fault, for instance, there's a company in Spain that has got an agreement with some of the Spanish airports, they use blockchain and their solution seems to work. I'm out of this share and just keeping an eye on it but don't blame blockchain, which is just a kind of database
I agree, results were quite good considering they were for 2019. I believe many were waiting for a sales update or forecast too, that is what causing the price to go down. Don't know how low it'll go this time, I'm watching closely to see if I can find a buying opportunity here
The pain relief cream and the CBD cream are the other products in development, that alongside the erectogenic cream makes a total of 3 potential killer apps for Futura. Market seems focusing solely on the impotence market
Extract from a recent RNS, I would like to know if that's still on track:
CBD100 - Futura's advanced proprietary transdermal technology, DermaSys® for the delivery of Cannabidiol
Futura announced a joint venture collaboration with CBDerma Technology Limited in September 2019 to explore the application of Futura's advanced proprietary transdermal technology, DermaSys® for the delivery of Cannabidiol.
CBDerma Technology is a company that has been established and funded to specifically exploit the therapeutic potential of Cannabis. The company's management, backers and advisors have extensive knowledge, expertise and investments in plant derived product manufacturing.
As part of the agreement, Futura will develop and optimise a DermaSys® cannabidiol formulation as well as establish early ex-vivo proof of concept studies likely to include certain disease states most suited for local or regional (non-systemic) topical treatment such as pain relief. Optimisation work is progressing, and the first stage of this will complete by the end of July 2020 before the next stage of potential ex-vivo proof of concept studies are being considered.